Our CEO Joanna Shields is presenting at the Times Tech Summit on why we need to use AI for life, not just lifestyle.
We hear so much about how technology is transforming life as we know it -- from autonomous vehicles to the likely prospect of space travel to Mars -- so why then does the treatment of disease still represent one of the greatest unmet human needs?
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
